AbbVie (ABBV) Interest & Investment Income (2012 - 2026)

AbbVie (ABBV) has reported Interest & Investment Income for 15 consecutive years, with -$679.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Interest & Investment Income changed 0.15% year-over-year to -$679.0 million in Q2 2026; TTM through Jun 2026 was -$2.6 billion, a 5.59% decrease from a year earlier, with the FY2025 full-year figure at -$2.6 billion, down 21.62% from the prior year.
• Interest & Investment Income was -$679.0 million for Q2 2026 at AbbVie, down from -$645.0 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at -$378.0 million in Q4 2023 and troughed at -$679.0 million in Q2 2026.
• A 5-year average of -$546.6 million and a median of -$535.5 million in 2022 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income rose 20.59% in 2023 and tumbled 61.38% in 2024, its largest moves.
• Over 5 years, Interest & Investment Income stood at -$476.0 million in 2022, then climbed by 20.59% to -$378.0 million in 2023, then plunged by 61.38% to -$610.0 million in 2024, then dropped by 7.38% to -$655.0 million in 2025, then dropped by 3.66% to -$679.0 million in 2026.
• The last three Interest & Investment Income figures came in at -$679.0 million (Q2 2026), -$645.0 million (Q1 2026), and -$655.0 million (Q4 2025), per Business Quant data.